Suppr超能文献

C 反应蛋白和中性粒细胞与淋巴细胞比值可预测 2019 年冠状病毒病患者的死亡率。

C-reactive protein and neutrophil-lymphocyte ratio as predictors of mortality in coronavirus disease 2019.

机构信息

Ayancik State Hospital, Department of Internal Medicine - Sinop, Turkey.

Atatürk Public Hospital, Department of emergency medicine - Sinop, Turkey.

出版信息

Rev Assoc Med Bras (1992). 2021 Oct;67(10):1498-1502. doi: 10.1590/1806-9282.20210679.

Abstract

OBJECTIVE

This study investigates whether C-reactive protein, platelet-lymphocyte ratio, and neutrophil-lymphocyte ratio could be useful to predict mortality in COVID-19.

METHODS

Data of 635 patients with COVID-19 followed up in Sinop Ataturk State Hospital from February to May 2020 were evaluated retrospectively. Diagnosis of COVID-19 was made according to the interim guidance of the World Health Organization. Patients were grouped into two groups based on mortality as survived and non-survived patients. Age, gender, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and C-reactive protein of the groups were investigated and compared.

RESULTS

The mean age of the participants was 55.8±22.3 years. Among the patients, 584 survived and 51 patients died. Age was significantly different between the groups, 54.2±22.3 in the survived group and 75.6±11.1 in the dead group (p=0.000). In addition, neutrophil, C-reactive protein, and neutrophil-lymphocyte ratio values were significantly higher in the dead group (p=0.000). platelet-lymphocyte ratio was slightly higher in the dead group, but this difference was not significant (p=0.42). The area under the curve values for age, lymphocyte, platelet, C-reactive protein, and neutrophil-lymphocyte ratio are 0.797, 0.424, 0.485, 0.778, and 0.729, respectively.

CONCLUSIONS

Our results showed that neutrophil-lymphocyte ratio and C-reactive protein are significantly higher in patients leading to death and could be effective biomarkers in predicting COVID-19 fatality. Furthermore, C-reactive protein could be used as an independent biomarker to predict death in patients with COVID-19, regardless of gender and age (p=0.000).

摘要

目的

本研究旨在探讨 C 反应蛋白、血小板与淋巴细胞比值和中性粒细胞与淋巴细胞比值是否可用于预测 COVID-19 患者的死亡率。

方法

回顾性分析 2020 年 2 月至 5 月在锡诺普阿塔图尔克州立医院接受治疗的 635 例 COVID-19 患者的数据。COVID-19 的诊断依据世界卫生组织的临时指南。根据死亡率将患者分为存活组和非存活组。分析比较两组患者的年龄、性别、中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值和 C 反应蛋白。

结果

研究对象的平均年龄为 55.8±22.3 岁。在患者中,584 例存活,51 例死亡。两组间年龄差异有统计学意义,存活组为 54.2±22.3 岁,死亡组为 75.6±11.1 岁(p=0.000)。此外,死亡组的中性粒细胞、C 反应蛋白和中性粒细胞与淋巴细胞比值均显著升高(p=0.000)。死亡组的血小板与淋巴细胞比值略高,但差异无统计学意义(p=0.42)。年龄、淋巴细胞、血小板、C 反应蛋白和中性粒细胞与淋巴细胞比值的曲线下面积值分别为 0.797、0.424、0.485、0.778 和 0.729。

结论

本研究结果表明,导致死亡的 COVID-19 患者的中性粒细胞与淋巴细胞比值和 C 反应蛋白显著升高,可作为预测 COVID-19 病死率的有效生物标志物。此外,C 反应蛋白可作为 COVID-19 患者死亡的独立预测生物标志物,与性别和年龄无关(p=0.000)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验